Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kensey Nash's carotid device:

This article was originally published in Clinica

Executive Summary

Kensey Nash is entering the carotid market, after having gained European approval to use its embolic protection system - TriActiv ProGuard - in carotid stenting procedures. The product, which was launched in Europe last year for use in saphenous vein graft procedures, is designed for use in branched anatomy, such as those of the carotid arteries. It prevents material or debris, dislodged during stent procedures, from embolising and causing adverse events such as a heart attack or stroke. The Exton, Pennsylvania company estimates that around 50,000 carotid artery stenting procedures are currently performed worldwide each year, a small percentage of the over 500,000 people who suffer from carotid artery disease. A carotid clinical trial in the US is underway to support FDA clearance of the product.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel